Please login to the form below

squamous cell cancer

This page shows the latest squamous cell cancer news and features for those working in and with pharma, biotech and healthcare.

NICE lung cancer backing for Keytruda is biggest expansion yet

cell lung cancer (NSCLC) patients in combination with chemotherapy for up to two years. ... The availability of combination therapy is a huge leap forward in improving the prognosis of patients with non-squamous non-small cell lung cancer.”.

Latest news

Roche’s Tecentriq misses survival mark in frontline NSCLC

Keytruda proving hard to beat. Roche's hopes of challenging Merck &Co for a slice of the lucrative first-line non-small cell lung cancer (NSCLC) immunotherapy market have been set ... This is our third phase 3 trial in non-squamous non-small cell lung
China’s BeiGene raises $903m from Hong Kong IPO

The company – which has just started pivotal trials for its lead cancer immunotherapy tislelizumab and hopes to file it in China this year – is the ninth biotech to take advantage of ... cancer (NSCLC), hepatocellular carcinoma, and oesophageal
Bluebird and Celgene BCMA CAR-T kicks off ASCO

option for patients with metastatic squamous non-small cell lung cancer (NSCLC) - regardless of PD-L1 expression levels. ... bevacizumab) and chemo, and an overall survival analysis from IMpower150, which looked at the effects of adding Tecentriq to
Daily Brief: AstraZeneca's new San Fran home, Keytruda triumphs again, Novo branches out

Topline data from its Keynote 407 study of the drug as a first-line treatment for metastatic squamous non-small cell lung cancer (sNSCLC) met the dual primary endpoints of improved ... Previously untreated patients with the squamous NSCLC represent about
Roche eyes September FDA verdict for triple NSCLC therapy

Roche hot on the heels of Merck in first-line non-small cell lung cancer market. ... Roche is pairing Tecentriq and Avastin in multiple cancer indications, including renal cell carcinoma.

More from news
Approximately 0 fully matching, plus 47 partially matching documents found.

Latest Intelligence

Chinese biotech’s global ambitions

has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

BIND Therapeutics appoints Andrew Hirsch as permanent CEO

Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Therapy Watch expands oncology and IBD portfolios

Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director – Healthcare Marketing – Berks: Salary TBC

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Business Development Director – Health Education: excellent commission

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Systematic Reviewer - Oxford: Negotiable

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Principal Health Economist - North-West: Negotiable

Experienced Medical Writers: Competitive Salary and Benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Account Executive with progression to Account Manager, Me...: Excellent package

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Medical (Scientific) Director: £120, 000 benefits

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Manager / Account Director: Competative

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Associate Director: £75, 000-90, 000

Senior Account Manager: Competitive Salary Offered

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Healthcare Communications Account Directors x 2: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Medical Writer: Salary TBC

Account Director: Competitive Salary Offered

Subscribe to our email news alerts

PMHub

Add my company

Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...